In fiscal year 2021, 167 of the 199 patent settlements pharmaceutical companies filed with the Federal Trade Commission contained a clause that most reporting on drug pricing never mentions by name. It is not the reverse payment. It is not the 180-day exclusivity window. It is the acceleration clause, a provision buried inside the settlement and supply agreement that decides what happens to a negotiated generic entry date the moment someone else invalidates the patent first.[3]
Brand and generic companies negotiate everything else in a Hatch-Waxman settlement down to the day. The launch date. The royalty rate. The authorized-generic supply terms. But the clause that fires automatically, without a new round of negotiation, when a court or the Patent Trial and Appeal Board (PTAB) knocks out the patent ahead of schedule, is the one most outside counsel treat as boilerplate. It is not boilerplate. It has been the subject of three federal antitrust rulings, one state statute, and a jury trial over HIV drugs that ended with a $525 million settlement.[12][13]
The Short Answer
When a brand and a generic manufacturer settle Hatch-Waxman patent litigation, the settlement almost never sets a single, fixed entry date. Instead, 84 percent of settlements filed with the FTC in FY2021 gave the generic manufacturer a license to launch on the earlier of a fixed date or the date some other triggering event occurs, most often another generic launching first or a court ruling the patent invalid, unenforceable, or not infringed.[3] This is the acceleration clause. It comes in two forms: Most Favored Entry (MFE), which lets the settling generic match whatever earlier date anyone else gets, and Most Favored Entry Plus (MFEP), which goes further and restores or improves the settling generic’s position relative to later entrants. Courts have treated MFE clauses as close to presumptively lawful. MFEP clauses are a different story.[2]
What a Hatch-Waxman Settlement Actually Locks In
The ANDA and the Paragraph IV Certification
The 1984 Hatch-Waxman Act lets a generic manufacturer file an Abbreviated New Drug Application (ANDA) that relies on the brand company’s own safety and efficacy data, provided the generic certifies what it intends to do about the brand’s Orange Book-listed patents. A Paragraph IV certification tells the FDA the generic believes those patents are invalid or will not be infringed. Filing it is, by statute, an act of patent infringement, which is what gives a federal court jurisdiction before a single tablet is sold. If the brand sues within 45 days, FDA approval of the ANDA is automatically stayed for up to 30 months or until the litigation ends, whichever comes first.[1]
The first company to file a Paragraph IV certification against a given patent earns 180 days of marketing exclusivity once it starts selling, a period the Supreme Court has described as potentially worth several hundred million dollars.[1] That number is the gravity well around which every settlement negotiation, and every acceleration clause, actually orbits.
The Patent-Term Split
Most Paragraph IV cases do not go to trial. They settle on a patent-term split: the generic agrees not to launch until a date somewhere between the settlement and the patent’s expiration, in exchange for a license to enter on that date without further litigation risk. A brand manufacturer confident of a 90 percent chance of winning at trial might still rationally grant entry at 90 percent of the remaining patent term, because certainty has value on both sides of the table.[2] None of this requires a cash payment, and the Supreme Court has been explicit that a pure patent-term split, without compensation, does not violate antitrust law.[2]
The problem the acceleration clause solves is what happens to that negotiated date if somebody else moves first.
The Acceleration Clause: MFE vs. MFEP
Without an acceleration clause, a settling generic that accepted, say, an entry date four years before patent expiration would have every incentive to be the last generic to settle, not the first, because any generic that keeps litigating and wins gets to launch immediately while the settling company waits out its negotiated date. That dynamic makes early settlement irrational, and it is why acceleration provisions showed up in at least 181 of 226 settlements the FTC reviewed in FY2016 and in 167 of 199 in FY2021.[2][3]
Most Favored Entry (MFE)
An MFE clause gives the settling generic the right to enter on the same date as any other generic that gets an earlier date, whether through its own settlement, a court win, or an at-risk launch. If nobody beats the settlement date, the MFE does nothing. If somebody does, the settling generic simply catches up. A federal court in the Southern District of New York described this structure as neutral in the absence of a trigger and procompetitive when triggered, because it multiplies the number of generics on the market rather than restricting it.[7]
Most Favored Entry Plus (MFEP)
An MFEP clause does more than match. It typically preserves or restores something extra for the settling generic, commonly a period of exclusivity relative to later filers, when an earlier entry event occurs. That extra value is exactly what turned two subsequent cases into multi-year litigation.
167 of the 199 final Hatch-Waxman patent settlements the FTC received in fiscal year 2021 contained an acceleration clause, and 166 of those 167 tied the generic’s entry date to a specific external trigger event rather than a fixed calendar date alone.[3]
How Common Is This, and What Actually Triggers It
The FTC’s FY2021 report lists the five most common events that move a licensed entry date forward: another company selling a generic version of the branded product; another company obtaining a final court decision of patent invalidity, unenforceability, or non-infringement; the brand manufacturer licensing a third party to an earlier date; branded product sales falling below a specified threshold; or the brand manufacturer winning FDA approval for a competing product with the same active ingredient.[3] Notably, the second category does not distinguish between a district court ruling and a final PTAB decision in an inter partes review, both count as “a final court decision” for purposes of what the FTC tracks, and both have triggered acceleration clauses in practice.[3][17]
Original Analysis: What 18 Years of FTC Filing Data Shows
The FTC has published fiscal year data on these settlements since 2004. Reading the agency’s own exhibit table across that period shows a pattern the individual annual reports do not spell out on their own: genuine cash reverse payments, as distinct from settlements that merely reimburse litigation fees, effectively disappeared after the Supreme Court’s 2013 Actavis decision.
Fiscal Year
Final Settlements Filed
With Restriction + Any Compensation
With Restriction + Compensation Above Litigation Fees
2010
113
31
17
2011
156
28
25
2012
140
40
33
2013
145
29
15
2014 (post-Actavis)
160
21
11
2015
170
14
5
2016
232
30
1
2017
226
20
3
2018
245
38
2
2019
194
24
3
2020
205
20
1
2021
199
33
0
Source: compiled from Exhibit 1 of the FTC’s FY2021 MMA report, which aggregates figures the agency has published in each annual filing since 2004.[3] The final column is the FTC’s own count of settlements with compensation exceeding litigation-fee reimbursement of $7 million or less; the year-over-year comparison and framing are this article’s analysis of that published data.
The number of settlements containing compensation above the litigation-fee threshold fell from 33 in FY2012, the year before Actavis, to zero in FY2021, even as the total number of settlements filed each year stayed roughly flat or grew. Brand and generic companies did not stop settling. They stopped using cash as the mechanism, and shifted structural value, including acceleration terms, quantity restrictions, and authorized-generic supply arrangements, into the agreements instead.[4] The FTC’s own January 2025 staff post makes the same point about quantity restrictions specifically, noting 23 agreements involving eight different drug products restricted how much product a settling generic could sell during a defined period, a term staff now watches as closely as cash.[4]
Case Study: Actos and the Court That Called Acceleration Procompetitive
Takeda’s diabetes drug Actos (pioglitazone) generated roughly $2.7 billion in U.S. sales in the twelve months before generic entry.[6] In December 2010, Takeda completed settlements with Mylan, Ranbaxy, Watson, Alphapharm, and Sandoz that granted each a license to sell generic Actos beginning August 17, 2012, or earlier under certain circumstances, roughly four years before the underlying patents were set to expire in 2016.[5] Takeda separately licensed Teva to sell an authorized generic version of Actos on the same date, or earlier under the same triggering language, an arrangement that functioned as a supply agreement layered on top of the litigation settlement.[5]
Mylan launched on the scheduled date of August 17, 2012, after receiving final FDA approval as the first generic entrant.[6] A putative class of indirect purchasers later sued Takeda and the settling generics, arguing that the MFE clauses in these agreements functioned as reverse payments because they discouraged other, non-settling generics from litigating to a win. In September 2015, U.S. District Judge Ronnie Abrams dismissed the case, holding that the generic manufacturers received no compensation from Takeda, only the ability to compete earlier if a trigger occurred, and that such competition would benefit consumers rather than harm them.[7] The court found the MFE clauses either neutral, if no trigger occurred, or procompetitive, if one did, and rejected the theory that merely discouraging other generics from litigating amounted to an antitrust violation.[2][7]
Case Study: Loestrin 24 Fe and the Three-Week Trigger
Warner Chilcott’s oral contraceptive Loestrin 24 Fe was protected by the ‘394 Patent, listed in the Orange Book after FDA approval in February 2006.[10] In January 2009, Warner Chilcott settled Paragraph IV litigation with Watson Pharmaceuticals, granting Watson a license to launch its generic on the earliest of three dates: January 22, 2014; 180 days before Warner granted a third party rights to enter; or the date any third party actually entered the U.S. market without Warner’s authorization.[8] In October 2010, Warner Chilcott separately settled with Lupin, which agreed not to launch until the earlier of July 22, 2014 or the date of an unauthorized “at-risk” entry by a third party.[9]
An end-payor class sued, alleging the Watson agreement’s MFEP structure, which preserved Watson’s 180-day exclusivity if triggered early, amounted to a reverse payment because it discouraged Lupin and other generics from litigating to a faster win. A federal court in the District of Rhode Island denied Warner Chilcott’s motion to dismiss in 2017, finding the plaintiffs had plausibly alleged the acceleration clause was one component of an unlawful reverse payment.[2] On summary judgment, Warner Chilcott argued the undisputed facts showed the opposite: Watson actually launched its generic three weeks earlier than its base entry date because the acceleration clause was triggered, which Warner Chilcott framed as proof the clause expedited competition rather than delaying it.[2] The court denied summary judgment in January 2020, holding a reasonable jury could still find the clause anticompetitive based on expert testimony that, absent it, generics would have entered even earlier and that the clause deterred later filers from litigating past Watson.[2]
Case Study: Truvada, Atripla, and the Gilead Jury Verdict
Gilead’s HIV combination drugs Truvada and Atripla, both built around the compound emtricitabine (FTC), generated the company’s largest antitrust exposure to date over acceleration clauses. Teva filed the first Paragraph IV ANDAs against Gilead’s emtricitabine patents. After a bench trial but before a final ruling, Gilead and Teva settled, with Teva agreeing to delay entry in exchange for both an MFE and an MFEP, described in the litigation as “essentially an acceleration provision.”[12] Gilead put MFE clauses into its Viread agreements and MFE/MFEP combinations into the Truvada and Atripla agreements with multiple generic manufacturers.[12]
A consolidated class action, Staley v. Gilead Sciences, later reorganized as In re HIV Antitrust Litigation, alleged these clauses delayed generic entry and deterred second-filers from racing past Teva. The court denied Gilead’s motion to dismiss in 2020, distinguishing the Actos ruling on the ground that Teva’s negotiated entry dates sat close to the patents’ actual expiration, in one instance only six weeks before expiration, and that the MFEP resurrected 180-day exclusivity Teva had already forfeited, a fact pattern the court called a “closer call” than a pure MFE.[2] The case proceeded to a jury trial on the MFE/MFEP theory in 2023. In May 2023, Gilead settled with the direct purchaser class and retailer opt-out plaintiffs for $525 million.[13] The remaining Phase I claims, covering Truvada and Atripla, went to verdict in June 2023, and the jury found in Gilead’s favor.[13] A separate end-payor settlement followed in October 2023, with Gilead agreeing to pay $246,750,000 into a settlement fund resolving the remaining claims.[14]
Read together, the two outcomes are not contradictory. A jury cleared Gilead’s MFE/MFEP conduct on the merits after trial, while Gilead still paid roughly $772 million combined to resolve overlapping claims that predated and ran alongside that verdict, a reminder that litigation risk and litigation outcome are two different numbers on the same balance sheet.
Case
Drug(s)
Clause Type
Documented Trigger
Outcome
In re Actos End Payor Antitrust Litig. (S.D.N.Y. 2015)
Pioglitazone (Actos)
MFE
Mylan’s scheduled launch, Aug. 17, 2012
Motion to dismiss granted; MFE held not anticompetitive[7]
In re Loestrin 24 Fe Antitrust Litig. (D.R.I. 2017, 2020)
Motion to dismiss and summary judgment both denied; jury question left open[2]
Staley v. Gilead / In re HIV Antitrust Litig. (N.D. Cal. 2020, 2023)
Emtricitabine-based (Truvada, Atripla)
MFE + MFEP
Entry dates as close as 6 weeks to patent expiration[12]
Motion to dismiss denied; jury verdict for Gilead on merits, $772M combined in separate class settlements[13][14]
The IPR Wrinkle: When a Board, Not a Court, Invalidates the Patent First
Congress created inter partes review (IPR) in 2011 as a faster, cheaper alternative to district court litigation for challenging patent validity, with the PTAB required to issue a final written decision within roughly 18 months of institution, against a median federal court time-to-trial of well over two years in the busiest ANDA venues.[17] Generic manufacturers noticed quickly. Within two years of the IPR mechanism’s availability, Apotex and Ranbaxy had both used early PTAB findings, rulings that a challenged patent claim would more likely than not be found invalid, as leverage to extract settlements from brand patent owners in separate proceedings.[17]
This matters for acceleration clauses because the FTC’s own trigger-event list does not distinguish a “final court decision” of invalidity from a final PTAB decision.[3] A generic that is not a party to a given settlement, and has no acceleration clause of its own, can still win an IPR against the same patent and trigger every MFE or MFEP clause tied to it across every other settled generic’s agreement simultaneously. The FTC has also made clear that a settlement resolving an IPR or post-grant review on a standalone basis must still be filed under the MMA if it involves a brand company, a generic company, and the ANDA-covered product, regardless of which forum, court or PTAB, produced the underlying dispute.[18] In FY2021, seven of the 199 final settlements the FTC reviewed involved simultaneous resolution of an IPR or post-grant review alongside the district court litigation, and none of the seven involved compensation to the generic.[3]
For a brand manufacturer, this converts patent strategy into portfolio management. An acceleration clause written around “a final court decision of invalidity” is, in practice, written around whichever generic manufacturer, settled or not, files the strongest IPR petition. Teams that track Orange Book listings, PTAB filings, and ANDA litigation across a drug’s full patent estate, the kind of monitoring that resources like DrugPatentWatch are built to support, are working from the same trigger conditions that show up in the settlement language itself.
Drafting Around the “Yellow Flag”
Reading Actos, Loestrin, and Staley together, the FDLI’s 2020 analysis by Cristina Fernandez and Michael Keeley distilled a practical pattern for structuring acceleration clauses to survive antitrust scrutiny.[2] Three elements recur across the rulings that went a brand’s way and are absent from the ones that did not:
Preserve an incentive for other generics to keep litigating rather than wait, for example by limiting the brand from offering any later-settling generic a more favorable date than the first, or capping an MFEP’s benefit at 180 days after the first-settling generic’s entry.
Limit MFEP-style added value to cases where the settling generic actually holds first-filer 180-day exclusivity at the time of settlement, rather than using the clause to resurrect exclusivity a generic already forfeited, the specific fact that hurt Warner Chilcott and Gilead.
Set the negotiated entry date meaningfully earlier than the patent’s true expiration, not clustered close to it, since a settlement date sitting six weeks from expiration was the detail the Staley court flagged as a warning sign.[2]
The Staley court itself put the underlying distinction directly: an MFE alone guarantees a second filer equality with the first, a closer legal question, while an MFEP can guarantee a second filer a worse position even where no exclusivity is at stake, a harder one to defend.[2]
California’s AB 824: A State Law Overlay With an Unsettled Ending
California Assembly Bill 824, effective January 1, 2020, took a different approach than the federal case-by-case rule of reason. It presumes a Hatch-Waxman settlement is anticompetitive and unlawful if the generic receives anything of value and does not immediately begin selling its product, defining “anything of value” broadly enough to include exclusive licenses.[2] The statute exempts pure early-entry licenses and certain dosage-based acceleration clauses from that presumption, but its reach is effectively national, because settlements are rarely structured to exclude California specifically.[2]
The Association for Accessible Medicines sued to block enforcement almost immediately. An early version of the suit was dismissed for lack of standing after the Ninth Circuit found the plaintiff’s member declarations did not allege any actual intent to enter a settlement the law would block.[15] AAM refiled, and in late 2021 the Eastern District of California, per Judge Troy Nunley, granted a preliminary injunction, finding AB 824 likely violates the Dormant Commerce Clause by regulating conduct that occurs largely outside the state.[15] As of the most recently available docket activity, the case remains on appeal before the Ninth Circuit under a new case number, meaning AB 824’s ultimate enforceability is still not finally resolved.[16]
What This Means for Brand Manufacturers
An acceleration clause is not a courtesy extended to a settling generic. It is consideration, and the FTC, private plaintiffs, and now California all treat it as something that can be valued, and therefore litigated, on the same terms as cash. The Actos outcome shows a narrowly drafted MFE, tied purely to matching another generic’s actual entry, carries real protection. The Loestrin and Staley outcomes show that stacking an MFEP on top, especially one that revives forfeited exclusivity or sets the base entry date close to patent expiration, invites years of discovery even when the brand ultimately prevails, as Gilead did on the jury verdict itself while still paying out on parallel settlements.[13][14]
What This Means for Generic and Biosimilar Challengers
The 166-of-167 statistic from FY2021 is the practical takeaway for any generic evaluating a settlement offer: an acceleration clause without a specific, enforceable trigger is close to unheard of, and a settling generic should expect the brand’s counsel to negotiate the trigger definition as hard as the base entry date.[3] Whether that trigger includes a PTAB final written decision, and not only a district court judgment, determines whether a generic that stays out of active litigation can still benefit for free when a different, more aggressive challenger wins an IPR.[3][17]
Methodology
Case selection: the three settlements profiled (Actos, Loestrin 24 Fe, Truvada/Atripla) were selected because each produced a reported federal court ruling directly addressing whether an MFE or MFEP acceleration clause could constitute an unlawful reverse payment, and each involved publicly available primary-source settlement terms through SEC filings, company press releases, or court dockets. Aggregate statistics on settlement prevalence and trigger events are drawn directly from the FTC’s own published FY2016 and FY2021 Bureau of Competition reports under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.[2][3] The multi-year compensation trend table reproduces the FTC’s own Exhibit 1 figures from the FY2021 report, which the agency has maintained on a consistent basis since FY2004; the year-over-year framing and the observation that the “above litigation fees” column falls to zero by FY2021 is this article’s own analysis of that published dataset, not a figure independently reported by the FTC as a standalone finding. Litigation status for California AB 824 reflects the most recent publicly available docket information as of this writing and may have changed since publication given the case remains on appeal.
Frequently Asked Questions
What is an acceleration clause in a Hatch-Waxman settlement?
It is a provision that lets a generic manufacturer begin selling its product before its negotiated settlement date if a specified triggering event occurs first, most commonly another generic entering the market or a court or PTAB ruling the patent invalid.[3]
What is the difference between MFE and MFEP?
MFE (Most Favored Entry) lets the settling generic match an earlier date obtained by anyone else. MFEP (Most Favored Entry Plus) goes further, typically preserving or restoring a period of exclusivity or comparative advantage for the settling generic when triggered.[2]
Do acceleration clauses violate antitrust law?
Not automatically. Courts apply the rule-of-reason framework from FTC v. Actavis. A pure MFE has fared well in litigation, notably in the Actos case, while MFEP structures have survived motions to dismiss and summary judgment against them, leaving the question for a jury in cases like Loestrin and the Gilead HIV litigation.[2][7][12]
Can an inter partes review trigger an acceleration clause?
Yes. The FTC’s trigger-event categories include a final court decision of invalidity, unenforceability, or non-infringement, and PTAB final written decisions in an IPR fall within how the agency tracks these events. Settlements resolving an IPR must still be filed with the FTC under the MMA.[3][18]
How common are acceleration clauses today?
In FY2021, 167 of 199 final Hatch-Waxman settlements filed with the FTC contained one, essentially unchanged from the FY2016 rate of 181 of 226.[2][3]
Did Gilead lose the Truvada and Atripla antitrust case?
A jury found in Gilead’s favor on the MFE/MFEP claims at trial in June 2023. Gilead nonetheless paid $525 million to a direct purchaser class in May 2023 and $246,750,000 to an end-payor class in October 2023 to resolve related, overlapping claims that were settled separately from the verdict.[13][14]
What happened in the Actos case?
A federal court dismissed antitrust claims against Takeda’s MFE clauses with Mylan, Ranbaxy, Watson, and other generics in 2015, holding the clauses were either neutral or procompetitive because they only compensated generics through market competition, not through payments from Takeda.[7]
What is California AB 824 and does it still apply?
AB 824 is a 2019 California statute that presumes certain Hatch-Waxman settlements are anticompetitive. A federal court preliminarily enjoined its enforcement in late 2021 on Dormant Commerce Clause grounds, and the case remains on appeal, so its final status is not yet settled.[15][16]
Why do brand companies grant acceleration clauses at all?
Without one, a settling generic has every incentive to hold out for the last settlement rather than the first, since later settlers or trial winners could otherwise leapfrog an earlier, more restrictive deal. Acceleration clauses make early settlement rational for the generic, which is what lets the brand achieve overall settlement predictability.[2]
What should a brand manufacturer’s legal team watch for when drafting these clauses?
Based on how courts have ruled, the highest-risk pattern combines an MFEP structure, an entry date clustered close to patent expiration, and a clause that restores exclusivity a generic already forfeited. A narrower MFE tied strictly to matching another generic’s actual market entry has fared better in litigation to date.[2][7]
Key Takeaways
167 of 199 Hatch-Waxman patent settlements filed with the FTC in FY2021 contained an acceleration clause, and 166 tied it to a specific external trigger event.[3]
Cash reverse payments above litigation-fee levels fell from 33 settlements in FY2012 to zero in FY2021, based on this article’s analysis of the FTC’s own published exhibit data.[3]
Courts have treated pure MFE clauses more favorably than MFEP clauses, which layer additional exclusivity-related value on top of simple date-matching.[2]
A final PTAB decision in an inter partes review can trigger the same acceleration language as a district court ruling, and settlements resolving IPRs must still be filed with the FTC.[3][18]
Gilead’s HIV drug litigation shows a brand can win the underlying jury verdict on an MFE/MFEP theory and still pay hundreds of millions of dollars to resolve overlapping class claims.[13][14]
California’s AB 824 remains under Dormant Commerce Clause challenge, with its enforceability still unresolved on appeal.[16]
References
FTC v. Actavis, Inc., 570 U.S. 136 (2013), as described in Impax Laboratories, Inc. v. FTC, No. 19-60394 (5th Cir. 2021), https://www.ca5.uscourts.gov/Opinions/pub/19/19-60394-CV0.pdf
Cristina M. Fernandez & Michael Keeley, “Antitrust Treatment of Acceleration Provisions in Hatch-Waxman Settlements,” Food and Drug Law Institute (Dec. 3, 2020, updated Apr. 23, 2021), https://www.fdli.org/2020/12/antitrust-treatment-of-acceleration-provisions-in-hatch-waxman-settlements/
Federal Trade Commission, Bureau of Competition, “Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in FY 2021” (published Jan. 16, 2025), https://www.ftc.gov/system/files/ftc_gov/pdf/fy-2021-mma-report.pdf
Brad Albert & Hannah Lamb, “Reverse Payments: From Cash to Quantity Restrictions and Other Possibilities,” FTC Competition Matters (Jan. 15, 2025), https://www.ftc.gov/enforcement/competition-matters/2025/01/reverse-payments-cash-quantity-restrictions-other-possibilities
Takeda Pharmaceutical Company Limited, “Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS…” PRNewswire (Dec. 21, 2010), https://www.prnewswire.com/news-releases/takeda-completes-settlements-with-all-defendants-in-us-patent-litigation-involving-actos-pioglitazone-hci-actoplus-met-pioglitazone-hcl-and-metformin-hcl-and-duetact-pioglitazone-hcl-and-glimepiride-112280449.html
GaBI Online, “FDA approval for generic diabetes drug Actos,” https://www.gabionline.net/generics/news/FDA-approval-for-generic-diabetes-drug-Actos
Kirkland & Ellis LLP, “Actos Pay-For-Delay Class Action Gets The Boot” (Sept. 23, 2015), summarizing In re Actos End Payor Antitrust Litig., No. 13-cv-9244 (S.D.N.Y. Sept. 22, 2015), https://www.kirkland.com/news/in-the-news/2015/09/actos-payfordelay-class-action-gets-the-boot
Warner Chilcott plc, Annual Report (Form 10-K), Fiscal Year 2010, U.S. Securities and Exchange Commission EDGAR, https://www.sec.gov/Archives/edgar/data/0001323854/000119312511046464/d10k.htm
Warner Chilcott plc, Quarterly Report (Form 10-Q), Fiscal Year 2012, U.S. Securities and Exchange Commission EDGAR, https://www.sec.gov/Archives/edgar/data/0001323854/000119312512462032/d420511d10q.htm
In re Loestrin 24 Fe Antitrust Litigation, 814 F.3d 538 (1st Cir. 2016), https://media.ca1.uscourts.gov/pdf.opinions/14-2071P-01A.pdf
In re HIV Antitrust Litigation, N.D. Cal. (2023), https://caselaw.findlaw.com/court/us-dis-crt-n-d-cal/2198180.html
Staley v. Gilead Sciences, Inc., 3:19-cv-02573, Consolidated Amended Complaint and related filings, N.D. Cal., https://www.docketalarm.com/cases/California_Northern_District_Court/3–19-cv-02573/Staley_et_al_v._Gilead_Sciences_Inc._et_al/788/
Gilead Sciences, Inc., Quarterly Report (Form 10-Q), quarter ended June 30, 2023, U.S. Securities and Exchange Commission EDGAR, https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/Financial_Report.xlsx
Roberts Law Firm US, PC and NastLaw LLC, press release re Truvada/Atripla direct purchaser settlement, BusinessWire (Oct. 9, 2023), https://www.businesswire.com/news/home/20231009932398/en/
California Lawyers Association, “AAM v. Robert Bonta: An End To California Pharmaceutical Legislative Reform?” Competition, Spring 2022, Vol. 32, No. 1, https://calawyers.org/publications/antitrust-unfair-competition-law/competition-spring-2022-vol-32-no-1-aam-v-robert-bonta-an-end-to-california-pharmaceutical-legislative-reform/
Justia Dockets & Filings, Association for Accessible Medicines v. Bonta, No. 25-1694 (9th Cir.), https://dockets.justia.com/docket/circuit-courts/ca9/25-1694
“After a Slow Start, Generic Pharmaceutical Companies Now Accelerate Their Use of Inter Partes Review Patent Challenges,” Healthcare Law Insights (2014), https://www.healthcarelawinsights.com/2014/04/after-a-slow-start-generic-pharmaceutical-companies-now-accelerate-their-use-of-inter-partes-review-patent-challenges/
Federal Trade Commission, “Then, Now, and Down the Road: Trends in Pharmaceutical Patent Settlements After FTC v. Actavis,” FTC Competition Matters (2019), https://www.ftc.gov/enforcement/competition-matters/2019/05/then-now-down-road-trends-pharmaceutical-patent-settlements-after-ftc-v-actavis
